{"id":17,"date":"2023-09-04T20:51:09","date_gmt":"2023-09-04T20:51:09","guid":{"rendered":"https:\/\/www.merckconnect.com\/bridion\/?page_id=17"},"modified":"2025-07-29T13:15:02","modified_gmt":"2025-07-29T13:15:02","slug":"neuromuscular-blockade-reversal","status":"publish","type":"page","link":"https:\/\/www.merckconnect.com\/bridion\/neuromuscular-blockade-reversal\/","title":{"rendered":"Moderate Block & Deep Block Recovery | Rocuronium and Vecuronium-Induced NMB"},"content":{"rendered":"\n\n

Efficacy for BRIDION\u00ae<\/sup> (sugammadex)<\/strong><\/h2><\/div>\n\n\n\n

Recovery from moderate and deep block<\/strong><\/h1><\/div>\n\n\n\n

Following rocuronium-induced moderate NMB, BRIDION demonstrated rapid recovery to a TOF ratio of 0.9<\/h3><\/div>\n\n\n\n\n
<\/div>\n\n\n\n\n
\"Percentage\"Percentage<\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\n
\"Minutes\"Minutes<\/figure><\/div>\n\n\n\n

Moderate block study design 3,4<\/sup><\/strong><\/h4><\/div>\n\n\n\n

Multicenter, randomized, parallel-group, active-controlled, safety-assessor-blinded study compared the efficacy of 2 mg\/kg of BRIDION vs 50 \u03bcg\/kg of neostigmine and 10 \u03bcg\/kg of glycopyrrolate for reversal of rocuronium- or vecuronium-induced moderate NMB (reappearance of T2<\/sub>) in 189 patients (87 women and 102 men, ASA majority class 1, 2). Patients underwent elective procedures that were mainly endocrine; ocular; ear, nose, and throat; abdominal (gynecological, colorectal, urological); orthopedic; vascular; or dermatological in nature. An objective monitoring device (TOF-Watch\u00ae SX) was used to evaluate neuromuscular function, to measure the depth of block based on responses to TOF stimulation (TOF count or twitches), and to calculate the degree of recovery using TOF ratio (which cannot be calculated without an objective monitoring device).2,5<\/sup> The primary endpoint was the time from start of BRIDION or neostigmine administration to a TOF ratio of 0.9, which generally correlates with recovery from NMB.<\/p>\n\n\n\n

<\/div>\n\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n

Learn more about recovery from:<\/strong><\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n\n

Moderate block<\/h4>
\n\n

<\/p>\n\n<\/div>

Moderate block<\/a><\/p><\/div>

<\/i><\/div><\/div><\/div><\/div>\n\n\n\n

Deep block<\/h4>
\n\n

<\/p>\n\n<\/div>

Deep block<\/a><\/p><\/div>

<\/i><\/div><\/div><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n

Recovery from moderate block<\/strong><\/h2><\/div>\n\n\n\n

BRIDION\u00ae (sugammadex) achieved rapid recovery from moderate block following rocuronium- and vecuronium-induced neuromuscular blockade (NMB).<\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n

In a clinical study, BRIDION demonstrated significantly faster reversal of rocuronium-induced moderate NMB (reappearance of T2<\/sub>) to recovery of the train-of-four (TOF) ratio to 0.9 vs neostigmine.3<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n
\"Median\"Median<\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\n

Vecuronium:<\/strong> Median time from vecuronium-induced moderate NMB to a TOF ratio of 0.9 was 2.1 minutes following administration of 2 mg\/kg of BRIDION (Quartiles [Q1, Q3]: 1.8, 3.4 minutes; n=48) vs a median time of 29.0 minutes (Quartiles [Q1, Q3]: 12.2, 76.2 minutes; n=45) following administration of 50 \u03bcg\/kg of neostigmine and 10 \u03bcg\/kg of glycopyrrolate.4<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n

Moderate block study design3,4<\/sup><\/strong><\/h4><\/div>\n\n\n\n

Multicenter, randomized, parallel-group, active-controlled, safety-assessor-blinded study compared the efficacy of 2 mg\/kg of BRIDION vs 50 \u03bcg\/kg of neostigmine and 10 \u03bcg\/kg of glycopyrrolate for reversal of rocuronium- or vecuronium-induced moderate NMB (reappearance of T2<\/sub>) in 189 patients (87 women and 102 men, ASA majority class 1, 2). Patients underwent elective procedures that were mainly endocrine; ocular; ear, nose, and throat; abdominal (gynecological, colorectal, urological); orthopedic; vascular; or dermatological in nature. An objective monitoring device (TOF-Watch\u00ae SX) was used to evaluate neuromuscular function, to measure the depth of block based on responses to TOF stimulation (TOF count or twitches), and to calculate the degree of recovery using TOF ratio (which cannot be calculated without an objective monitoring device).2,5<\/sup> The primary endpoint was the time from start of BRIDION or neostigmine administration to a TOF ratio of 0.9, which generally correlates with recovery from NMB.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Recovery from deep block<\/strong><\/h2><\/div>\n\n\n\n

BRIDION\u00ae (sugammadex) provided rapid recovery from deep block.<\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n

In a clinical study, BRIDION demonstrated rapid recovery from rocuronium-induced deep NMB (1-2 post-tetanic counts [PTCs]) to recovery of the train-of-four (TOF) ratio to 0.9.6<\/sup><\/p><\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\"Geometric\"Geometric<\/figure><\/div>\n\n\n\n\n